Watson to sell a generic of J&J's Concerta for ADHD
Executive Summary
Watson Laboratories Inc. has signed an exclusive distribution agreement for a generic version of Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals Inc.'s (OMJPI) blockbuster drug Concerta (methylphenidate) extended-release tablets. The product is approved for ADHD in children 6-12 years old and adults up to the age of 65 as part of a program that may include counseling.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Manufacturing or Supply
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice